-
Mashup Score: 5
Both metabolic dysfunction and alcohol consumption cause steatotic liver disease (SLD). The distinction between metabolic dysfunction-associated SLD (MASLD) and MetALD categories is based on arbitrary thresholds of alcohol intake. Thus, we assessed the impact of different levels of alcohol consumption on SLD severity and their interaction with metabolic comorbidities.
Source: www.journal-of-hepatology.euCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 77
Liver transplantation (LT) represents the best treatment option for patients with selected hepatocellular carcinoma (HCC) but due to organ shortage most regions place limits on the size and number of tumors that qualify for this therapy. The best methods to prevent drop-out from the waiting list due to tumor progression and/or to reduce post-transplant tumor recurrence are unknown [1]. According to the American Association for the Study of Liver Diseases guidelines for the management of HCC, bridging therapies should be applied if the expected waiting time is longer than 6months [2].
Source: www.journal-of-hepatology.euCategories: General Medicine News, Hem/OncsTweet-
Another setting where SBRT underutilized IMO in HCC is bridge to transplant. I am convinced w modern tech, SBRT can safely prevent local progression in most. Study shows similar transplant outcomes post SBRT/TACE/RFA, despite SBRT pts w worse liver fxn https://t.co/svrVvwzjy2
-
-
Mashup Score: 34FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond - 2 month(s) ago
The worldwide epidemics of obesity, hypertriglyceridemia, dyslipidaemia, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) represent a major economic burden on healthcare systems. Patients with at-risk MASH, defined as MASH with moderate or significant fibrosis, are at higher risk of comorbidity/mortality, with a significant risk of cardiovascular diseases and/or major adverse liver outcomes. Despite a high unmet medical need, there is only one drug approved for MASH.
Source: www.journal-of-hepatology.euCategories: General Medicine News, CardiologistsTweet-
RT @scottisaacsmd: Mechanism of Action of #FGF21 analogues for #MASLD and #MASH. https://t.co/UYJofvCvv5 https://t.co/sxQKICYOLL
-
-
Mashup Score: 34FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond - 2 month(s) ago
The worldwide epidemics of obesity, hypertriglyceridemia, dyslipidaemia, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) represent a major economic burden on healthcare systems. Patients with at-risk MASH, defined as MASH with moderate or significant fibrosis, are at higher risk of comorbidity/mortality, with a significant risk of cardiovascular diseases and/or major adverse liver outcomes. Despite a high unmet medical need, there is only one drug approved for MASH.
Source: www.journal-of-hepatology.euCategories: General Medicine News, CardiologistsTweet-
RT @scottisaacsmd: Mechanism of Action of #FGF21 analogues for #MASLD and #MASH. https://t.co/UYJofvCvv5 https://t.co/sxQKICYOLL
-
-
Mashup Score: 7Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma - 4 month(s) ago
In the global, phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) improved overall survival (OS) vs. sorafenib; durvalumab was noninferior to sorafenib. HBV is the predominant HCC aetiology in most of Asia vs. HCV or nonviral aetiologies in Western countries and Japan. This analysis evaluated safety and efficacy outcomes for STRIDE and durvalumab monotherapy vs. sorafenib, in HIMALAYA participants enrolled in Asia, excluding Japan.
Source: www.journal-of-hepatology.euCategories: General Medicine News, Hem/OncsTweet-
Added key points of @MSKCancerCenter @MSK_DeptOfMed and worldwide collegaues Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma - Journal of Hepatology https://t.co/pdaGy53zWB
-
-
Mashup Score: 11Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis - 12 month(s) ago
We read with great interest the recent paper titled “Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?”. There was a debate among the authors about whether hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT) are candidates for liver transplantation (LT). Soin et al. reported significant long-term survival benefits from liver transplantation in HCC and PVTT patients after successful downstaging. However, Lesurtel et al.
Source: www.journal-of-hepatology.euCategories: General Medicine News, General HCPsTweet-
Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis #some4surgery https://t.co/eIZOc2Ubku
-
-
Mashup Score: 9Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients - 1 year(s) ago
Comparative assessments of immunogenicity following different COVID-19 vaccines in patients with distinct liver diseases are lacking. SARS-CoV-2 specific T cell and antibody responses were evaluated longitudinally after one to three vaccines alongside COVID-19 clinical outcomes.
Source: www.journal-of-hepatology.euCategories: General Medicine News, Infectious DiseaseTweet-
#SARSCoV2 specific T cell and antibody responses were evaluated longitudinally after one to three vaccines 💉 alongside #COVID19 clinical outcomes. Patients with liver disease generally developed robust #antibody and T-cell responses. @JHepatology | https://t.co/gwAWIzr8WI https://t.co/5d8WXZPG7S
-
-
Mashup Score: 22Gilbert’s syndrome revisited - 1 year(s) ago
Gilbert’s syndrome, also known as benign hyperbilirubinaemia, was described more than 100 years ago. It has usually been considered a physiological abnormality characterised by a mild elevation of the systemic level of unconjugated bilirubin, in the absence of any underlying liver or overt haemolytic disease. However, since the re-discovery of the potent antioxidant effects of bilirubin in the late 1980s, as well as multiple intracellular signalling pathways affected by bilirubin, an ever-increasing body of evidence suggests that individuals with Gilbert’s syndrome may benefit from the mild hyperbilirubinaemia and are actually protected from the development of a wide variety of “diseases of civilisation” such as cardiovascular diseases, certain cancers, and autoimmune or neurodegenerative diseases.
Source: www.journal-of-hepatology.euCategories: Hematologists1, Latest HeadlinesTweet-
RT @JHepatology: 🆕REVIEW❕ Gilbert’s syndrome revisited 🔓#OpenAccess at👉https://t.co/pMseE3aikq #LiverTwitter https://t.co/CEKVQfXGLN
-
This is an alarming study on the additive effects of even moderate alcohol consumption on fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Bottom line: No safe limit of EtOH intake if MASLD. https://t.co/YNHr9ym67O